Quantitative Virus-Associated RNA Detection to Monitor Oncolytic Adenovirus Replication

Author:

Brachtlova Tereza1234,Li Jing13,van der Meulen-Muileman Ida H.13ORCID,Sluiter Femke1,von Meijenfeldt Willem1,Witte Isabella1,Massaar Sanne1ORCID,van den Oever Ruben5,de Vrij Jeroen56,van Beusechem Victor W.1234

Affiliation:

1. Medical Oncology, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands

2. ORCA Therapeutics BV, 5223 DE ‘s-Hertogenbosch, The Netherlands

3. Cancer Biology and Immunology, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands

4. Cancer Immunology, Amsterdam Institute for Infection and Immunity, 1081 HV Amsterdam, The Netherlands

5. Department of Neurosurgery, Erasmus MC, 3015 GD Rotterdam, The Netherlands

6. ExoVectory BV, Biopartner 2 Building, 2333 CH Leiden, The Netherlands

Abstract

Oncolytic adenoviruses are in development as immunotherapeutic agents for solid tumors. Their efficacy is in part dependent on their ability to replicate in tumors. It is, however, difficult to obtain evidence for intratumoral oncolytic adenovirus replication if direct access to the tumor is not possible. Detection of systemic adenovirus DNA, which is sometimes used as a proxy, has limited value because it does not distinguish between the product of intratumoral replication and injected virus that did not replicate. Therefore, we investigated if detection of virus-associated RNA (VA RNA) by RT-qPCR on liquid biopsies could be used as an alternative. We found that VA RNA is expressed in adenovirus-infected cells in a replication-dependent manner and is secreted by these cells in association with extracellular vesicles. This allowed VA RNA detection in the peripheral blood of a preclinical in vivo model carrying adenovirus-injected human tumors and on liquid biopsies from a human clinical trial. Our results confirm that VA RNA detection in liquid biopsies can be used for minimally invasive assessment of oncolytic adenovirus replication in solid tumors in vivo.

Funder

European Union’s Horizon 2020 research and innovation program

Publisher

MDPI AG

Reference40 articles.

1. Mantwill, K., Klein, F.G., Wang, D., Hindupur, S.V., Ehrenfeld, M., Holm, P.S., and Nawroth, R. (2021). Concepts in Oncolytic Adenovirus Therapy. Int. J. Mol. Sci., 22.

2. Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus;Alemany;Clin. Cancer Res.,2021

3. A Phase I Trial of CV706, a Replication-Competent, PSA Selective Oncolytic Adenovirus, for the Treatment of Locally Recurrent Prostate Cancer Following Radiation Therapy;DeWeese;Cancer Res.,2001

4. Hepatic Arterial Infusion of a Replication-Selective Oncolytic Adenovirus (Dl1520): Phase II Viral, Immunologic, and Clinical Endpoints;Reid;Cancer Res.,2002

5. A Phase 1 Dose Escalation Study of the Oncolytic Adenovirus Enadenotucirev, Administered Intravenously to Patients with Epithelial Solid Tumors (EVOLVE);Machiels;J. Immunother. Cancer,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3